VIVEK SUBBIAH to Genes, erbB
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Genes, erbB.
Connection Strength
0.058
-
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
Score: 0.058